PT1401442E - S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas) - Google Patents

S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas)

Info

Publication number
PT1401442E
PT1401442E PT02776528T PT02776528T PT1401442E PT 1401442 E PT1401442 E PT 1401442E PT 02776528 T PT02776528 T PT 02776528T PT 02776528 T PT02776528 T PT 02776528T PT 1401442 E PT1401442 E PT 1401442E
Authority
PT
Portugal
Prior art keywords
omeprazolo
esomeprazole
cyclodextrins
inclusion complex
cyclodextrin
Prior art date
Application number
PT02776528T
Other languages
English (en)
Portuguese (pt)
Inventor
Hamied Yusuf Khwaja
Rao Dharmaraj Ramachandra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of PT1401442E publication Critical patent/PT1401442E/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT02776528T 2001-06-06 2002-06-06 S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas) PT1401442E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex

Publications (1)

Publication Number Publication Date
PT1401442E true PT1401442E (pt) 2005-02-28

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02776528T PT1401442E (pt) 2001-06-06 2002-06-06 S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas)

Country Status (17)

Country Link
US (1) US20040147481A1 (enExample)
EP (1) EP1401442B1 (enExample)
JP (1) JP2004536810A (enExample)
AT (1) ATE282412T1 (enExample)
AU (1) AU2002344386B2 (enExample)
CA (1) CA2449769C (enExample)
DE (1) DE60201995T2 (enExample)
ES (1) ES2232780T3 (enExample)
GB (1) GB2376231A (enExample)
LT (1) LT5182B (enExample)
LV (1) LV13154B (enExample)
NZ (1) NZ529956A (enExample)
PL (1) PL366940A1 (enExample)
PT (1) PT1401442E (enExample)
RU (1) RU2313343C2 (enExample)
WO (1) WO2002098423A1 (enExample)
ZA (1) ZA200309841B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
CA2631459A1 (en) 2005-12-28 2007-07-05 Union Quimico Farmaceutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 s-오메프라졸 함유 포접 복합체 및이의 제조방법
PT2106397E (pt) 2007-09-25 2012-01-23 Hetero Drugs Ltd Processo para a preparação de esomeprazol enantiomericamente puro
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (enExample) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CA2282513C (en) * 1997-03-13 2007-09-18 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
EP1018340B1 (en) * 1999-01-06 2003-09-10 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
EP1206466B1 (en) * 1999-08-26 2005-10-12 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
ES2232780T3 (es) 2005-06-01
CA2449769A1 (en) 2002-12-12
LV13154B (en) 2004-07-20
US20040147481A1 (en) 2004-07-29
CA2449769C (en) 2010-12-14
DE60201995T2 (de) 2005-11-24
ATE282412T1 (de) 2004-12-15
GB0113792D0 (en) 2001-07-25
EP1401442A1 (en) 2004-03-31
HK1064602A1 (en) 2005-02-04
ZA200309841B (en) 2005-03-14
LT2003100A (en) 2004-09-27
NZ529956A (en) 2005-07-29
JP2004536810A (ja) 2004-12-09
LT5182B (lt) 2004-12-27
PL366940A1 (en) 2005-02-07
AU2002344386B2 (en) 2006-11-30
EP1401442B1 (en) 2004-11-17
DE60201995D1 (de) 2004-12-23
WO2002098423A1 (en) 2002-12-12
GB2376231A (en) 2002-12-11
RU2313343C2 (ru) 2007-12-27
RU2003137221A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
CO5611163A2 (es) Formulaciones de solucion que contienen anticuerpos
DE60212163D1 (de) Kontrolliertes wirkstoffabgabesystem
NO20030374L (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
EA200200316A1 (ru) Соединения для лечения ишемии
AR033096A1 (es) Acomposicion antifungal con aumentada biodisponibilidad
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
MXPA04006210A (es) Composiciones acuosas que contienen metronidazole.
DK1784232T3 (da) Biologisk aktive klæbeartikler og fremgangsmåder til fremstilling
NO20040074L (no) Fremgangsmåte for fremstilling av benzimidazoltype forbindelser
ECSP066662A (es) Preparación farmacéutica que comprende un anticuerpo contra el receptor egf
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
ATE282412T1 (de) S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CO5930056A1 (es) Composiciones con ciclopopenos
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
ATE341319T1 (de) Esmolol-enthaltende zubereitungen
DE60321484D1 (de) Aktivitätsüberwachung
AR041639A1 (es) Metodo para la sintesis de un compuesto de bencimidazol
DK1305037T3 (da) Smertestillende medikament
PE20070378A1 (es) FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA
NO20041671L (no) Anthelmintic composition
ATE269313T1 (de) Tryptase-inhibitoren
ATE268322T1 (de) Inhibitoren der tryptase
DK1220844T3 (da) Arylsulfonamid-substituerede benzimidazolderivater og deres anvendelse som tryptase-inhibitorer